Consumption Coagulopathy Treatment & Management

1. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999 Aug 19. 341(8):586-92. [Medline].

2. Costello R, Nehring S. Disseminated Intravascular Coagulation (DIC). StatPearls. 2017 Jun. [Medline]. [Full Text].

3. Levi M, de Jonge E, Meijers J. The diagnosis of disseminated intravascular coagulation. Blood Rev. 2002 Dec. 16(4):217-23. [Medline].

4. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018 Feb 22. 131 (8):845-54. [Medline]. [Full Text].

5. Shimura M, Wada H, Wakita Y, et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol. 1997 Aug. 55(4):169-74. [Medline].

6. Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood. 2000 Feb 1. 95(3):930-5. [Medline].

7. Morel N, Morel O, Petit L, et al. Generation of procoagulant microparticles in cerebrospinal fluid and peripheral blood after traumatic brain injury. J Trauma. 2008 Mar. 64(3):698-704. [Medline].

8. Langer F, Spath B, Haubold K, Holstein K, Marx G, Wierecky J. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol. 2008 Jun. 87(6):451-7. [Medline].

9. Arbuthnot C, Wilde JT. Haemostatic problems in acute promyelocytic leukaemia. Blood Rev. 2006 Jun 3. [Medline].

10. Asakura H, Ontachi Y, Mizutani T, et al. Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases. Blood Coagul Fibrinolysis. 2001 Jan. 12(1):1-8. [Medline].

11. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 1997 Nov 15. 90 (10):3819-43. [Medline].

12. Grewal PK, Uchiyama S, Ditto D, Varki N, Le DT, Nizet V. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med. 2008 Jun. 14(6):648-55. [Medline].

13. Oren H, Cingoz I, Duman M. Disseminated intravascular coagulation in pediatric patients: clinical and laboratory features and prognostic factors influencing the survival. Pediatr Hematol Oncol. 2005 Dec. 22(8):679-88. [Medline].

14. Araki S, Tomioka S, Otani M, et al. Incidence and In-Hospital Mortality of Neonatal Disseminated Intravascular Coagulation in Japan: An Observational Study of a Nationwide Hospital Claims Database. J UOEH. 2019. 41 (3):295-302. [Medline]. [Full Text].

15. Sohn CH, Kim SR, Kim YJ, et al. Disseminated Intravascular Coagulation in Emergency Department Patients With Primary Postpartum Hemorrhage. Shock. 2017 Sep. 48 (3):329-32. [Medline].

16. Slatnick LR, Thornhill D, Deakyne Davies SJ, et al. Disseminated Intravascular Coagulation Is an Independent Predictor of Adverse Outcomes in Children in the Emergency Department with Suspected Sepsis. J Pediatr. 2020 Oct. 225:198-206.e2. [Medline].

17. Liras IN, Caplan HW, Stensballe J, Wade CE, Cox CS, Cotton BA. Prevalence and Impact of Admission Acute Traumatic Coagulopathy on Treatment Intensity, Resource Use, and Mortality: An Evaluation of 956 Severely Injured Children and Adolescents. J Am Coll Surg. 2017 Apr. 224 (4):625-32. [Medline].

18. Cunningham FG, Nelson DB. Disseminated Intravascular Coagulation Syndromes in Obstetrics. Obstet Gynecol. 2015 Oct 5. [Medline].

19. Hjorleifsson E, Sigurdsson MI, Gudmundsdottir BR, Sigurdsson GH, Onundarson PT. Prediction of survival in patients suspected of disseminated intravascular coagulation. Acta Anaesthesiol Scand. 2015 Aug. 59 (7):870-80. [Medline].

20. Taylor FB, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 Nov. 86(5):1327-30. [Medline].

21. Rajpurkar M, Alonzo TA, Wang YC, et al. Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children's Oncology Group Study AAML0631. J Pediatr Hematol Oncol. 2019 Jan. 41 (1):51-55. [Medline]. [Full Text].

22. Asakura H, Takahashi H, Uchiyama T, et al. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2016. 14:42. [Medline]. [Full Text].

23. Wada H. Disseminated intravascular coagulation. Clin Chim Acta. 2004 Jun. 344(1-2):13-21. [Medline].

24. Dempfle CE, Wurst M, Smolinski M, et al. Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score. Thromb Haemost. 2004 Apr. 91(4):812-8. [Medline].

25. Voves C, Wuillemin WA, Zeerleder S. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagul Fibrinolysis. 2006 Sep. 17(6):445-51. [Medline].

26. Soundar EP, Jariwala P, Nguyen TC, Eldin KW, Teruya J. Evaluation of the international society on thrombosis and haemostasis and institutional diagnostic criteria of disseminated intravascular coagulation in pediatric patients. Am J Clin Pathol. 2013 Jun. 139(6):812-6. [Medline].

27. Lee DH, Lee BK, Jeung KW, et al. Disseminated intravascular coagulation is associated with the neurologic outcome of cardiac arrest survivors. Am J Emerg Med. 2017 May 1. [Medline].

28. Ettingshausen CE, Veldmann A, Beeg T, Schneider W, Jäger G, Kreuz W. Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost. 1999. 25(6):537-41. [Medline].

29. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood. 2000 Dec 1. 96(12):3719-24. [Medline].

30. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 8. 344(10):699-709. [Medline].

31. Schellongowski P, Bauer E, Holzinger U, Staudinger T, Frass M, Laczika K. Treatment of adult patients with sepsis-induced coagulopathy and purpura fulminans using a plasma-derived protein C concentrate (Ceprotin). Vox Sang. 2006 May. 90(4):294-301. [Medline].

32. Yilmaz D, Karapinar B, Balkan C, Akisu M, Kavakli K. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. Pediatr Hematol Oncol. 2008 Jun. 25(4):301-11. [Medline].

33. Fischer D, Schloesser R, Buxmann H, Veldman A. Recombinant activated Factor VII as a hemostatic agent in very low birth weight preterms with gastrointestinal hemorrhage and disseminated intravascular coagulation. J Pediatr Hematol Oncol. 2008 May. 30(5):337-42. [Medline].

34. Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet. 2007 Mar 10. 369(9564):836-43. [Medline].

35. Marti-Carvajal AJ, Comunian-Carrasco G, Pena-Marti GE. Haematological interventions for treating disseminated intravascular coagulation during pregnancy and postpartum. Cochrane Database Syst Rev. 2011 Mar 16. 3:CD008577. [Medline].

36. Chi S, Ikezoe T. Disseminated intravascular coagulation in non-Hodgkin lymphoma. Int J Hematol. 2015 Oct. 102 (4):413-9. [Medline].

Himal M Shah, MBBS, MD, DM Hematologist and Stem Cell Transplant Physician, Ahmedabad, India

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Gary D Crouch, MD Associate Professor, Program Director of Pediatric Hematology-Oncology Fellowship, Department of Pediatrics, Uniformed Services University of the Health Sciences

Gary D Crouch, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Hematology

Disclosure: Nothing to disclose.

Vikramjit S Kanwar, MBBS, MBA, MRCP(UK), FAAP Professor Emeritus of Pediatrics, Albany Medical College

Vikramjit S Kanwar, MBBS, MBA, MRCP(UK), FAAP is a member of the following medical societies: American Academy of Pediatrics, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Children's Oncology Group, International Society of Pediatric Oncology

Disclosure: Nothing to disclose.

Richard H Sills, MD Professor of Pediatrics, State University of New York Upstate Medical University

Richard H Sills, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Alexander Gozman, MD Assistant Professor, Department of Pediatrics, Division of Hematology/Oncology, Albany Medical Center

Alexander Gozman, MD is a member of the following medical societies: American Medical Association, American Society of Clinical Oncology, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Children's Oncology Group

Disclosure: Nothing to disclose.

Jennifer Boden Cerone, MD Resident Physician, Department of Pediatrics, The Children’s Hospital at Albany Medical Center

Jennifer Boden Cerone is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Paul J Galardy, MD Instructor, Department of Pediatrics, Massachusetts General Hospital for Children and Harvard Medical School

Disclosure: Nothing to disclose.

Eric Grabowski, MD, ScD Director of Cardiovascular Thrombosis Laboratory, Massachusetts General Hospital for Children; Associate Professor, Department of Pediatrics, Division of Hematology-Oncology, Harvard Medical School

Disclosure: Nothing to disclose.

Gary R Jones, MD Associate Medical Director, Clinical Development, Berlex Laboratories

Gary R Jones, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Pediatric Hematology/Oncology, and Western Society for Pediatric Research

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article